Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Click here to view

Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing